Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)±folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients

European Journal of Cancer

Volumn 36, Issue 18, 2000, Pages 2335-2343

  Bensmane, M A ^a   De Gramont, A ^b   Brienza, S ^c   Marty, M ^d   Levi F ^e   Ducreux, M ^f   Francois E ^g   Gamelin, E ^h   Bleiberg, H ⁱ   Bleuzen, P ^a   Simon, J ^a   Cvitkovic, E ^a,e  

^a Cvitkovic et Associes Consultants   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Debiopharm ^*  (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Centre Lacassagne   (France)

^h CENTRE PAUL PAPIN   (France)

ⁱ JULES BORDET INSTITUTE   (Belgium)

Author keywords

Clinical resistance; Multivariate analysis; Salvage chemotherapy

Indexed keywords

ALKALINE PHOSPHATASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONOPHARMACOLOGY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 0033695520     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00305-1     Document Type: Article

References (36)

1. Cancer statistics 1992 CA
2. Low-dose protracted continuous 5-fluorouracil infusion in solid tumors
3. High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: Results of a phase II study
4. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
5. A phase II study of 5-fluorouracil plus cisplatin for metastatic colorectal adenocarcinoma: A South-west Oncology Group (SWOG) study
6. Protracted venous 5-Fluorouracil infusion and weekly cisplatin in metastatic colorectal cancer
7. Low-dose continuous infusion 5-fluorouracil and cisplatin: Phase II evaluation in advanced colorectal carcinoma
8. Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma
9. Chemotherapy with cisplatinum (CDDP) and 5FU in metastatic colorectal cancer
10. Royal Mardsen phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer
11. Oxaliplatin: A review of preclinical and clinical studies
12. Oxaliplatin: Mechanism of action and antineoplastic activity
13. Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous venous infusion at circadian-rhythm modulated rate
14. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
15. Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients
16. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer
17. Addition of oxaliplatin (Eloxatin®) to the same leucovorin (LV) and 5-fluorouracil (5-FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report
18. Oxaliplatin combined to 5-FU and folinic acid (5-FU/FA) as second or third line treatment in patients with advanced colorectal cancer (CRC)
19. Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC)
20. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump
21. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer
22. Addition of oxaliplatin (L-OHP(r)) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer (ACC)
23. Reporting results of cancer treatment
24. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer
25. Regression models and life-tables
26. Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: An effective second-line regimen
27. Continuous-infusion 5-Fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: Clinical evidence of incomplete cross-resistance
28. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (Leucovorin) in patients with colorectal cancer metastases a randomized multi-institutional trial
29. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
30. Influence of measurement error on assesment of response to anticancer chemotherapy: Proposal for new criteria of tumor response
31. Oxaliplatin combined to 5-fluorouracil and folinic acid: An effective salvage therapy in patients with advanced colorectal cancer
32. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
33. Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics
34. Oxaliplatin (L-OHP) and irinotecan (CPT-11) phase I/II studies: Results in 5-FU refractory (FR) colorectal cancer (CRC) patients (pts)
35. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer